###begin article-title 0
###xml 18 23 <span type="species:ncbi:9606">Human</span>
The Importance of Human FcgammaRI in Mediating Protection to Malaria
###end article-title 0
###begin p 1
###xml 184 205 184 205 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 526 540 526 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P. falciparum.</italic>
###xml 704 717 704 717 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 154 159 <span type="species:ncbi:9606">human</span>
###xml 184 205 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 461 467 <span type="species:ncbi:9606">humans</span>
###xml 526 539 <span type="species:ncbi:5833">P. falciparum</span>
###xml 624 629 <span type="species:ncbi:9606">human</span>
###xml 704 717 <span type="species:ncbi:5833">P. falciparum</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
###xml 755 760 <span type="species:ncbi:9606">human</span>
###xml 781 786 <span type="species:ncbi:9606">human</span>
###xml 891 896 <span type="species:ncbi:9606">human</span>
###xml 1069 1074 <span type="species:ncbi:9606">human</span>
The success of passive immunization suggests that antibody-based therapies will be effective at controlling malaria. We describe the development of fully human antibodies specific for Plasmodium falciparum by antibody repertoire cloning from phage display libraries generated from immune Gambian adults. Although these novel reagents bind with strong affinity to malaria parasites, it remains unclear if in vitro assays are predictive of functional immunity in humans, due to the lack of suitable animal models permissive for P. falciparum. A potentially useful solution described herein allows the antimalarial efficacy of human antibodies to be determined using rodent malaria parasites transgenic for P. falciparum antigens in mice also transgenic for human Fc-receptors. These human IgG1s cured animals of an otherwise lethal malaria infection, and protection was crucially dependent on human FcgammaRI. This important finding documents the capacity of FcgammaRI to mediate potent antimalaria immunity and supports the development of FcgammaRI-directed therapy for human malaria.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 756 778 756 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium falciparum.</italic>
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 83 88 <span type="species:ncbi:9606">child</span>
###xml 692 698 <span type="species:ncbi:9606">humans</span>
###xml 756 777 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 816 821 <span type="species:ncbi:10090">mouse</span>
###xml 920 925 <span type="species:ncbi:9606">human</span>
###xml 1169 1175 <span type="species:ncbi:9606">humans</span>
Malaria rivals HIV and tuberculosis as the world's most deadly infection killing a child every 30 seconds. Antibodies and their receptors (Fc-receptors) have been shown to be vital for the development of protective immunity, and as such they act as correlates of protection in studies aimed at defining the best antigens to incorporate into current vaccines. Understanding antibody types and Fc-receptors that optimally induce immunity is therefore vital to developing the best vaccines. Surrogate markers of antibody efficacy currently rely on in vitro assays that are laborious and difficult to reproduce. It remains unclear if such in vitro assays are predictive of functional immunity in humans due to the lack of suitable animal models permissive for Plasmodium falciparum. Here, we create a transgenic in vivo mouse model that has significant advantage over the use of new world primates, the only other model for human malaria. We demonstrate that this model defines an Fc-dependent mechanism of parasite destruction that cannot be assessed in current in vitro assays. The model provides both a test for therapeutic antibody efficacy prior to clinical trials in humans and an important tool in malaria vaccine development.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 70 71 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b001">1</xref>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b002">2</xref>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b003">3</xref>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b004">4</xref>
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b005">5</xref>
###xml 452 454 452 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 576 577 576 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b006">6</xref>
###xml 638 639 638 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b007">7</xref>
###xml 745 766 745 766 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 776 777 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b008">8</xref>
###xml 903 904 903 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b009">9</xref>
###xml 52 58 <span type="species:ncbi:9606">people</span>
###xml 113 119 <span type="species:ncbi:9606">humans</span>
###xml 745 766 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Malaria continues to kill approximately 2-3 million people each year [1]. The success of passive immunization in humans and animals suggests that immunoglobulin (Ig)-based therapies could be effective [2,3]. Manipulating antibody (Ab) genes allows the design of Ig with defined class and specificity, targeting protective epitopes on the parasite surface [4,5]. An appropriate target is the 19-kDa C-terminal region of merozoite surface protein 1 (MSP119). This polypeptide displays limited sequence polymorphism possibly because the structure is constrained by its function [6], is expressed by all vertebrate asexual life-cycle stages [7], and acts as a major target of the erythrocyte invasion-inhibitory Ab response in individuals immune to Plasmodium falciparum malaria [8]. Novel genetic approaches, including linkage-group selection, have also identified MSP1 as an important target of immunity [9].
###end p 6
###begin p 7
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b005">5</xref>
###xml 485 487 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b010">10</xref>
###xml 488 490 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b011">11</xref>
###xml 680 683 650 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 856 859 822 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1002 1020 968 986 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium berghei</named-content>
###xml 1036 1038 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b010">10</xref>
###xml 1064 1081 1030 1047 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium yoelii</named-content>
###xml 1178 1180 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b011">11</xref>
###xml 1525 1548 1483 1506 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Cryptococcus neoformans</named-content>
###xml 1603 1606 1557 1560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1613 1615 1567 1569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b012">12</xref>
###xml 1823 1825 1769 1771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b013">13</xref>
###xml 1953 1955 1891 1893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b014">14</xref>
###xml 1956 1958 1894 1896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b015">15</xref>
###xml 2090 2092 2016 2018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b016">16</xref>
###xml 2207 2209 2129 2131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b017">17</xref>
###xml 238 243 <span type="species:ncbi:10090">mouse</span>
###xml 276 281 <span type="species:ncbi:9606">human</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
###xml 1002 1020 <span type="species:ncbi:5821">Plasmodium berghei</span>
###xml 1064 1081 <span type="species:ncbi:5861">Plasmodium yoelii</span>
###xml 1504 1509 <span type="species:ncbi:10090">mouse</span>
###xml 1525 1537 <span type="species:ncbi:89924">Cryptococcus</span>
###xml 1525 1548 <span type="species:ncbi:5207">Cryptococcus neoformans</span>
###xml 1607 1611 <span type="species:ncbi:10090">mice</span>
###xml 1747 1753 <span type="species:ncbi:10090">murine</span>
###xml 1770 1775 <span type="species:ncbi:10090">mouse</span>
###xml 1863 1867 <span type="species:ncbi:10090">mice</span>
###xml 1936 1941 <span type="species:ncbi:10090">mouse</span>
###xml 2324 2329 <span type="species:ncbi:9606">human</span>
###xml 2334 2349 <span type="species:ncbi:10090">transgenic mice</span>
The mechanisms whereby Ig mediates protective immunity in malaria are less clear. The importance of Fc-receptor (FcR) subunits in malaria immunity has been studied in animals with FcR deletions. Although informative, these gene-deficient mouse models may not always mimic the human immune condition, due to differences in FcR biology and an apparent lack of true homologues [5]. Studies examining the role of FcR in immunity to parasites have made use of FcRgamma-chain knockout mice [10,11]. The gamma-chain, a subunit common to FcgammaRI, FcgammaRIIIa, FcepsilonRI, and FcalphaRI, is required for efficient cell surface expression and signal transduction. Consequently, FcRgamma-/- mice are unable to elicit phagocytosis or Ab-dependent cell-mediated cytotoxicity reactions through these receptors. Two recent studies with rodent malarias in the FcRgamma-/- have proved controversial, with one study showing a crucial role for FcR-mediated Ab-dependent phagocytosis in host resistance to blood-stage Plasmodium berghei XAT infection [10], and another study with Plasmodium yoelii concluding that the protective effects of Ab probably arise through FcR-independent mechanisms [11]. However, these studies ignore two important possibilities. Firstly, there might be other, as yet unidentified, FcR involved in the observed response, and secondly, the alpha-chain of many FcR may associate with other signaling proteins other than the common gamma-chain. With this in mind, it is interesting to note that mouse IgG3-opsonized Cryptococcus neoformans can still be phagocytosed by macrophages from FcRgamma-/- mice [12]. This effect is probably mediated via an undefined FcR without requiring gamma-chain for function because, of the known FcR, only murine FcgammaRI binds mouse IgG3, as demonstrated by transfection studies [13]. Secondly, FcRgamma-chain-deficient mice were found to express partially functional FcgammaRI in more recent mouse knockouts [14,15]. It is now known that the gamma-chain of FcgammaRI can mediate MHC class II Ag presentation without active gamma-chain signaling [16], and that the alpha-chain can interact with Periplakin to control receptor endocytosis and IgG binding capacity [17]. These potential drawbacks to the rodent FcgammaRI knockout model led us to investigate the possibility of using human FcR transgenic mice to investigate Ab function with relation to malaria.
###end p 7
###begin p 8
###xml 604 617 604 617 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b018">18</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b019">19</xref>
###xml 667 680 667 680 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 783 796 783 796 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 905 918 905 918 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 540 546 <span type="species:ncbi:9606">humans</span>
###xml 604 617 <span type="species:ncbi:5833">P. falciparum</span>
###xml 667 680 <span type="species:ncbi:5833">P. falciparum</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
###xml 718 723 <span type="species:ncbi:9606">human</span>
###xml 783 796 <span type="species:ncbi:5833">P. falciparum</span>
###xml 810 816 <span type="species:ncbi:9606">humans</span>
###xml 905 918 <span type="species:ncbi:5833">P. falciparum</span>
###xml 951 957 <span type="species:ncbi:9606">humans</span>
Antibodies have been shown to be vital for the development of protective immunity, and as such they act as correlates of protection in studies aimed at defining the best antigens to incorporate into current vaccines. Understanding which Ab and FcR combination optimally induces immunity is therefore vital to developing the best vaccines. Surrogate markers of Ab efficacy currently rely on in vitro assays that are laborious and difficult to reproduce and it remains unclear if such in vitro assays are predictive of functional immunity in humans due to the lack of suitable animal models permissive for P. falciparum [18,19]. By using rodent malarias transgenic for P. falciparum antigens in mice also transgenic for human FcRs, we have created a novel model that more fully mimics P. falciparum infection in humans, while providing an alternative to nonhuman primates for assessing the efficacy of anti-P. falciparum Abs prior to clinical trials in humans.
###end p 8
###begin p 9
###xml 51 64 51 64 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 69 71 69 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 51 64 <span type="species:ncbi:5833">P. falciparum</span>
###xml 248 253 <span type="species:ncbi:9606">human</span>
###xml 341 346 <span type="species:ncbi:9606">human</span>
Here, we create novel fully human Abs specific for P. falciparum MSP119 by Ab repertoire cloning from phage display libraries generated from malaria-immune Gambian adults. Using this unique dual transgenic approach, we were able to show that these human Abs are completely protective in vivo, and that this effect was crucially dependent on human FcgammaRI (CD64).
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
Development of Antibody Repertoire Phage Display Libraries from Malaria-Exposed Donors
###end title 11
###begin p 12
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 443 451 443 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g001">Figure 1</xref>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g001">1</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 735 737 735 737 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 785 798 785 798 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 838 846 838 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g001">Figure 1</xref>
###xml 975 988 975 988 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 1001 1009 1001 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g001">Figure 1</xref>
###xml 1011 1012 1011 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g001">1</xref>
###xml 1164 1166 1164 1166 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1175 1177 1175 1177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 1373 1375 1373 1375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1490 1492 1490 1492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 785 798 <span type="species:ncbi:5833">P. falciparum</span>
###xml 975 988 <span type="species:ncbi:5833">P. falciparum</span>
We describe the construction of two phage display libraries derived from blood donations from malaria-exposed donors. The combined size of the two libraries (~1.3 x 109 members) was sufficiently large to anticipate high affinity antibody fragments (unpublished data) [20]. PCR and BstNI fingerprinting of 100 randomly selected clones and their sequencing confirmed that they were derived from a wide range of different variable gene families (Figure 1A-1B). In additional experiments to estimate diversity, a number of clones were randomly sequenced from the unpanned libraries and found to be very diverse and derived from a wide range of different V gene families (unpublished data) [20]. Four rounds of panning with recombinant MSP119-GST yielded scFvs capable of strong binding to P. falciparum parasites by immunofluorescence (IFA) (Figure 1C). Immunoblotting confirmed that polyclonal scFv from later rounds of panning did bind native MSP1 from T9/96 and FCB-1-derived P. falciparum merozoites (Figure 1D-1E). Intriguingly, panning against whole merozoites in which MSP1 processing had been allowed to proceed, gave almost identical patterns recognizing MSP119 and MSP142 to that seen when libraries were panned on recombinant proteins. Additionally, the close sequence similarity between scFvs obtained by panning with either processed merozoites or recombinant MSP119 suggests that natural antibody responses to the merozoite after secondary processing are directed more toward MSP119 than any other antigen remaining on the merozoite surface.
###end p 12
###begin p 13
###xml 22 24 22 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 91 93 91 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 224 237 224 237 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 242 244 242 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 312 320 312 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g001">Figure 1</xref>
###xml 418 431 418 431 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b021">21</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b022">22</xref>
###xml 513 521 513 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g002">Figure 2</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 795 796 795 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b023">23</xref>
###xml 224 237 <span type="species:ncbi:5833">P. falciparum</span>
###xml 418 431 <span type="species:ncbi:5833">P. falciparum</span>
###xml 653 658 <span type="species:ncbi:9606">human</span>
Twenty individual MSP119-binding scFv clones selected on the basis of their binding to MSP119-GST by ELISA, their variety of restriction fragment patterns on BstNI digestion, and their ability to inhibit the binding of anti-P. falciparum MSP119 monoclonal antibodies (mAbs) 12.8 and 12.10 in competition ELISAs (Figure 1F) were sequenced. mAb 12.8 and 12.10 have been shown to inhibit erythrocyte invasion in vitro by P. falciparum merozoites [21,22]. Of these 20 clones, six different scFv sequences were found (Figure 2A). None of the six scFvs inhibited erythrocyte invasion in vitro [20]. We therefore engineered the most promising scFvs into fully human antibodies since the presence of the Fc may potentiate inhibition of erythrocyte invasion, a likely prediction given that Fab and F(ab')2 fragments of mAb 12.10 do not retain invasion-inhibitory properties [23]. Intriguingly, we have recently isolated scFv to other key malaria antigens from this library, including EBA-175 and EMP1 (unpublished data).
###end p 13
###begin title 14
###xml 49 62 49 62 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 67 69 67 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 25 30 <span type="species:ncbi:9606">Human</span>
###xml 49 62 <span type="species:ncbi:5833">P. falciparum</span>
Development of Two Fully Human IgG1s Recognizing P. falciparum MSP119
###end title 14
###begin p 15
###xml 208 217 208 217 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. yoelii</named-content>
###xml 222 224 222 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 509 517 509 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g003">Figure 3</xref>
###xml 546 559 546 559 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 564 566 564 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 587 595 587 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g003">Figure 3</xref>
###xml 745 755 745 755 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 781 794 781 794 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 799 801 799 801 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 933 943 933 943 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 948 950 948 950 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 961 969 961 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g003">Figure 3</xref>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b025">25</xref>
###xml 989 999 989 999 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 1004 1017 1004 1017 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 1022 1024 1022 1024 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1227 1235 1215 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g003">Figure 3</xref>
###xml 1387 1400 1375 1388 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 1405 1407 1393 1395 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1474 1476 1462 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b025">25</xref>
###xml 1526 1539 1514 1527 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 1558 1566 1546 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g003">Figure 3</xref>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 197 202 <span type="species:ncbi:9606">human</span>
###xml 208 217 <span type="species:ncbi:5861">P. yoelii</span>
###xml 546 559 <span type="species:ncbi:5833">P. falciparum</span>
###xml 745 755 <span type="species:ncbi:5821">P. berghei</span>
###xml 781 794 <span type="species:ncbi:5833">P. falciparum</span>
###xml 933 943 <span type="species:ncbi:5821">P. berghei</span>
###xml 989 999 <span type="species:ncbi:5821">P. berghei</span>
###xml 1004 1017 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1387 1400 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1414 1419 <span type="species:ncbi:9606">human</span>
###xml 1434 1438 <span type="species:ncbi:10090">mice</span>
###xml 1454 1459 <span type="species:ncbi:9606">human</span>
###xml 1526 1539 <span type="species:ncbi:5833">P. falciparum</span>
We subcloned the variable genes derived from two promising scFvs c1 and e9 and linked them to human IgG1 constant domains in expression vectors as previously used to successfully generate chimeric human anti-P. yoelii MSP119 IgG1s [24]. Both antibodies, now termed JS1 (derived from phage c1) or JS2 (derived from phage e9), when purified from CHO-K1 transfectant culture supernatants contained polypeptides of the expected sizes on SDS-PAGE and the anticipated reactivities with isotype-specific antibodies (Figure 3A). JS1 and JS2 recognized a P. falciparum MSP119-GST fusion protein (Figure 3B), and by indirect IFA, both antibodies produced a characteristic pattern of MSP1 reactivity in schizonts, merozoites, and ring-stage parasites from P. berghei parasites transgenic for P. falciparum MSP119 (PbPfM19), but not to the control transgenic line PbPbM19 previously engineered to integrate in an identical manner the homologous P. berghei MSP119 sequence (Figure 3C) [25]. The use of P. berghei and P. falciparum MSP119-specific antibodies (alphaPbM19 and alphaPfM19) allowed confirmation of the genotype of the transgenic lines while demonstrating that both JS1 and JS2 colocalize only with alphaPfM19 detecting reagent (Figure 3C, merge + brightfield). This novel rodent malaria model thus provides an alternative to nonhuman primates for assessing and monitoring the efficacy of P. falciparum MSP119-based human antibodies in mice transgenic for human Fc-receptors [25]. In addition, both JS1 and JS2 bound to the 3D7 P. falciparum reference strain (Figure 3D).
###end p 15
###begin p 16
###xml 96 98 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 167 175 167 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g002">Figure 2</xref>
###xml 262 275 262 275 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 280 282 280 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 415 417 415 417 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 140 145 <span type="species:ncbi:10090">mouse</span>
###xml 262 275 <span type="species:ncbi:5833">P. falciparum</span>
Importantly, surface plasmon resonance (SPR) analysis revealed no reduction in affinity for MSP119 for either JS1 or JS2 when compared with mouse mAbs 12.8 and 12.10 (Figure 2B). However, JS2 did have a reduced on-rate and therefore a lower overall affinity for P. falciparum MSP119 when compared with JS1, a finding that may explain the reduced potency seen with JS2 in vivo. Despite comparable affinities for MSP119, neither JS1 nor JS2 inhibited MSP1 processing when compared to mAb 12.8 (unpublished data, available on request).
###end p 16
###begin title 17
###xml 33 38 <span type="species:ncbi:9606">Human</span>
JS1 and JS2 Are Fully Functional Human IgG1 Antibodies
###end title 17
###begin p 18
###xml 67 69 67 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 103 111 103 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g004">Figure 4</xref>
###xml 161 163 161 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 169 182 169 182 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 466 474 466 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g004">Figure 4</xref>
###xml 499 501 499 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 505 507 505 507 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 169 182 <span type="species:ncbi:5833">P. falciparum</span>
###xml 208 213 <span type="species:ncbi:9606">human</span>
###xml 447 452 <span type="species:ncbi:9606">human</span>
###xml 570 575 <span type="species:ncbi:9606">human</span>
###xml 796 801 <span type="species:ncbi:9606">human</span>
We assessed the ability of these novel reagents to phagocytose MSP119-coated fluorescent microspheres (Figure 4A). Beads opsonized with JS1 Abs specific for MSP119 from P. falciparum could be detected within human neutrophils. The capacity to ingest these "pseudomerozoites" was enormous with up to 20 beads being detected in some neutrophils. We also assessed the ability of these novel reagents to elicit an oxidative burst and degranulation in human neutrophils (Figure 4B). When attached to GST-PfMSP119-coated plates at equimolar concentrations, an epitope matched human IgA1 recently constructed from the same variable genes as in JS1 (unpublished data) was consistently the most efficient at inducing respiratory bursts, although both JS1 and JS2 were also very effective. Since uninduced human neutrophils do not express many molecules of FcgammaRI, phagocytosis and respiratory bursts in this instance most likely occur through FcgammaRIIA and/or FcgammaRIIIB.
###end p 18
###begin title 19
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
Epitope Mapping of JS1 and JS2 Binding Sites on MSP119
###end title 19
###begin p 20
###xml 85 87 85 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 260 262 260 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 264 272 264 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g005">Figure 5</xref>
###xml 331 333 331 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 748 750 748 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 946 948 946 948 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b026">26</xref>
###xml 1133 1140 1133 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030072-t001">Table 1</xref>
###xml 1379 1381 1379 1381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sup>
###xml 1440 1442 1438 1440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sup>
###xml 1474 1476 1472 1474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 1504 1506 1502 1504 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 1697 1699 1693 1695 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sup>
###xml 1715 1717 1709 1711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">33</sup>
###xml 1901 1909 1893 1901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g006">Figure 6</xref>
###xml 1914 1921 1906 1913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030072-t001">Table 1</xref>
###xml 1958 1960 1950 1952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40</sup>
###xml 1965 1967 1957 1959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">29</sup>
###xml 1976 1978 1968 1970 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">39</sup>
###xml 2210 2211 2202 2203 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 2217 2218 2209 2210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 2308 2316 2300 2308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g002">Figure 2</xref>
###xml 2322 2329 2314 2321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030072-t001">Table 1</xref>
###xml 2483 2485 2475 2477 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 2513 2521 2505 2513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g006">Figure 6</xref>
###xml 2526 2533 2518 2525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030072-t001">Table 1</xref>
###xml 718 723 <span type="species:ncbi:9606">human</span>
A number of approaches were used in order to identify the amino acid residues in MSP119 contributing to the binding of JS1 and JS2. A competition ELISA was designed to determine whether JS1 or JS2 could compete with mAbs 12.8 or 12.10 for binding sites on MSP119 (Figure 5). Binding of either JS1 or JS2 reduced the binding to MSP119 of mAbs 12.8 and 12.10 by ~60% and 30%, respectively, suggesting that JS1 and JS2 compete with mAbs 12.8 and 12.10 for similar epitopes. JS1 and JS2 may therefore be described as blocking antibodies since they inhibit the binding of invasion inhibitory mAbs. Intriguingly, the converse experiment with 12.10 and 12.8 failed to inhibit binding of JS1 or JS2, suggesting that the fully human antibodies may bind MSP119 with a higher affinity and/or that the epitopes seen are nonidentical but overlapping. In order to identify the amino acid residues involved in JS1 and JS2 binding, we made use of a panel of MSP119 mutants available from a previous study investigating the binding of inhibitory and blocking mAbs [26]. Binding of Abs to the modified proteins was detected by ELISA and SPR analysis. Table 1 summarizes the effect of 11 single and six multiple amino acid substitutions on binding by JS1 and JS2 compared with the previously described effects on interaction with mAbs 12.10 and 12.8. Of these, only one amino acid substitution (Cys28-->Trp) completely ablated binding by both JS1 and JS2. Cys28 forms a disulfide bond with Cys12, the mutation of which (Cys12-->Ile) had no affect on binding by JS1 or JS2 but did completely prevent binding by the mAbs 12.10 and 12.8. Six further mutants had intermediate effects on binding by JS1 and JS2, with (Arg20-->Glu) and (Asn33-->Ile) being particularly prominent since no binding by SPR analysis was seen when these mutant proteins were passed over JS1 or JS2 at identical concentrations to wild-type protein (Figure 6 and Table 1). Three further substitutions at Lys40, Lys29, and Asn39 only had minor affects on binding. No differences in gross binding (other than minor differences in affinity) could be seen to distinguish JS1 from JS2, despite significant variability (20 amino acid substitutions throughout each VL and VH gene) within the complementarity determining regions of their respective variable genes (Figure 2A and Table 1). These findings support our assertion that JS1 and JS2 bind to nonidentical but overlapping residues in the first epidermal growth factor domain of MSP119, in common with mAbs 12.8 (Figure 6 and Table 1) and 12.10 (for which the epitope also has a contribution from the second epidermal growth factor domain).
###end p 20
###begin title 21
###xml 77 82 <span type="species:ncbi:9606">Human</span>
Suppression of Parasitemia by JS1 Is Critically Dependent on the Presence of Human FcgammaRI
###end title 21
###begin p 22
###xml 25 35 25 35 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 51 64 51 64 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 69 71 69 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 275 283 271 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g007">Figure 7</xref>
###xml 427 429 419 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 508 510 500 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 671 673 663 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 679 688 671 680 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. yoelii</named-content>
###xml 902 910 890 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g007">Figure 7</xref>
###xml 25 35 <span type="species:ncbi:5821">P. berghei</span>
###xml 51 64 <span type="species:ncbi:5833">P. falciparum</span>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 258 263 <span type="species:ncbi:9606">human</span>
###xml 412 417 <span type="species:ncbi:9606">human</span>
###xml 613 618 <span type="species:ncbi:9606">human</span>
###xml 638 643 <span type="species:ncbi:9606">human</span>
###xml 679 688 <span type="species:ncbi:5861">P. yoelii</span>
###xml 796 801 <span type="species:ncbi:9606">human</span>
In vivo experiments with P. berghei transgenic for P. falciparum MSP119 demonstrated that three intraperitoneal (i.p.) inoculations of JS1 (total dose of 1.5 mg antibody) effectively suppressed a lethal blood stage challenge infection in mice transgenic for human FcgammaRI (Figure 7A). However, JS1 was nonprotective in nontransgenic littermates allowing us to conclude that FcgammaRI recruitment by this fully human anti-MSP119 IgG1 is crucial for therapeutic effectiveness. A simple neutralization of MSP119 function by some form of steric hindrance is therefore insufficient to bring about protection by this human IgG1. As expected, human IgG1 (B10) recognizing MSP119 from P. yoelii was completely ineffective at controlling parasitemias, confirming that binding of transgenic FcgammaRI by human IgG1 is insufficient to induce protection in the absence of specific high-affinity antigen binding (Figure 7A).
###end p 22
###begin p 23
###xml 140 148 140 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g007">Figure 7</xref>
###xml 235 243 235 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g007">Figure 7</xref>
###xml 249 254 <span type="species:ncbi:10090">mouse</span>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 302 307 <span type="species:ncbi:9606">human</span>
###xml 424 429 <span type="species:ncbi:9606">human</span>
###xml 469 475 <span type="species:ncbi:10090">murine</span>
Further experiments with JS1 could show that a total dose of as little as 0.75 mg of antibody could result in effective parasite clearance (Figure 7B). Importantly, protection could be reversed with passive administration of mAb 10.1 (Figure 7B), a mouse mAb that binds to human FcgammaRI blocking the human IgG1 binding site, and allowing us to conclude that immune protection is crucially dependent on the presence of the human FcgammaRI transgene and not endogenous murine FcgammaRs. JS2 was equally effective at controlling malaria at the higher Ab dose of 1.5 mg/animal but was unable to prevent the development of parasitemia at lower doses (</=0.75 mg/animal) suggesting that subtle differences in affinity or fine-specificity can ultimately impact significantly on in vivo efficacy (unpublished data). Such a prediction could not have been envisaged from in vitro assays while confirming the importance of our in vivo model for screening antibodies that otherwise appear promising from initial in vitro screens.
###end p 23
###begin p 24
###xml 275 283 271 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g007">Figure 7</xref>
Although we were unable to detect free merozoites or infected erythrocytes from FcgammaRI transgenic animals treated with JS1, we did notice that many circulating phagocytes with classical monocyte type morphology contained Giemsa-staining merozoites within their cytoplasm (Figure 7C versus 7D and 7E).
###end p 24
###begin p 25
###xml 67 82 <span type="species:ncbi:10090">transgenic mice</span>
###xml 137 142 <span type="species:ncbi:9606">human</span>
There was no observable difference in the ability of the FcgammaRI transgenic mice versus nontransgenic animals in rates of clearance of human antibodies, work that has also recently been confirmed in animals lacking all FcgammaRs, suggesting that the neonatal FcR is wholly responsible for the kinetics of clearance (unpublished data).
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 97 99 97 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 105 119 105 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P. falciparum,</italic>
###xml 602 615 602 615 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b027">27</xref>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 105 118 <span type="species:ncbi:5833">P. falciparum</span>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 180 185 <span type="species:ncbi:9606">human</span>
###xml 338 343 <span type="species:ncbi:9606">human</span>
###xml 369 374 <span type="species:ncbi:9606">human</span>
###xml 477 482 <span type="species:ncbi:9606">human</span>
###xml 556 561 <span type="species:ncbi:9606">human</span>
###xml 602 615 <span type="species:ncbi:5833">P. falciparum</span>
We describe the development of the first fully human IgG1 with specificity for an epitope on MSP119 from P. falciparum, for dissecting human FcR mechanisms involved in immunity to human malaria. These antibodies may also be employed in the clinic as therapeutically useful entities. These novel reagents were generated through cloning of human Ig variable domains from human combinatorial phage display libraries derived from malaria immune Gambians and their engraftment onto human constant region genes, for expression in mammalian cells. Although fully human antibodies have been generated to other P. falciparum antigens, the Fc-receptors through which these antibodies confer their protective effects have not been elucidated [27].
###end p 27
###begin p 28
###xml 172 182 168 178 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 208 221 204 217 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 226 228 222 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 373 386 369 382 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 391 393 387 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 619 621 615 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 689 691 685 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 172 182 <span type="species:ncbi:5821">P. berghei</span>
###xml 208 221 <span type="species:ncbi:5833">P. falciparum</span>
###xml 233 237 <span type="species:ncbi:10090">mice</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 269 274 <span type="species:ncbi:9606">human</span>
###xml 373 386 <span type="species:ncbi:5833">P. falciparum</span>
###xml 425 430 <span type="species:ncbi:10090">mouse</span>
###xml 539 544 <span type="species:ncbi:9606">human</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
The engineered Abs recognized parasites in infected erythrocytes and triggered potent human FcgammaRI-mediated protection in a novel Ab testing system involving the use of P. berghei parasites transgenic for P. falciparum MSP119 and mice transgenic for human FcRs. The human Abs bound to nonidentical but overlapping residues in the first epidermal growth factor domain of P. falciparum MSP119 and with similar affinities to mouse mAbs, 12.10 and 12.8, already known to inhibit erythrocyte invasion in vitro. Importantly, the inability of human IgG1 to protect in nontransgenic mice indicates that mere blocking of MSP119 function by some form of steric hindrance or interference with MSP119 processing is insufficient to bring about protection, and that the presence of the Fc region is crucial, since this allows the recruitment of FcgammaRI-mediated parasite clearance. In contrast to mAb 12.10 and 12.8, neither JS1 nor JS2 could inhibit MSP1 processing in vitro (unpublished data), suggesting that their efficacy in vivo is wholly dependent on Fc-mediated pathways. It will be informative to determine if subcloning the V genes onto alternative Fc scaffolds, such as IgG3 and IgA, which having larger Fc regions and greater flexibility to the IgG1 created here, would confer processing inhibitory activity. Interestingly, the JS1 and JS2 antibodies would be classified as blocking antibodies that favor erythrocyte invasion using an in vitro assay, but here the in vivo assay shows that they are important in parasite destruction.
###end p 28
###begin p 29
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 871 872 871 872 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Since intact 12.10 and 12.8 can inhibit MSP1 processing and invasion of erythrocytes in in vitro assays and Fabs and F(ab')2 cannot, it is likely that the Fc portion of the antibody contributes in some way to this process. The Fc is of significant size (50 kDa) and is attached to the rest of the antibody via a flexible hinge that allows much wagging and flexibility in this region. Indeed the flexibility of the Fc is known to make an important contribution to function; therefore, it is not inconceivable that it may interfere with invasion by some form of steric hindrance of the merozoite. An alternative explanation not requiring FcR-bearing effector cells, is that complement plays a role in this process since only an intact antibody can activate the complement cascade and this occurs through the Fc-region, while explaining the lack of effect with Fabs or F(ab'2). However, inhibition of invasion assays are done with heat-inactivated serum or in the presence of Albumax in the place of serum, suggesting that complement does not play a role, at least in vitro.
###end p 29
###begin p 30
###xml 191 204 187 200 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 324 326 320 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 604 606 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b018">18</xref>
###xml 607 609 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b019">19</xref>
###xml 1135 1145 1131 1141 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 1195 1208 1191 1204 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 1449 1451 1445 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b028">28</xref>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 179 185 <span type="species:ncbi:9606">humans</span>
###xml 191 204 <span type="species:ncbi:5833">P. falciparum</span>
###xml 233 238 <span type="species:ncbi:9606">human</span>
###xml 462 468 <span type="species:ncbi:9606">humans</span>
###xml 489 494 <span type="species:ncbi:9606">human</span>
###xml 1135 1145 <span type="species:ncbi:5821">P. berghei</span>
###xml 1146 1151 <span type="species:ncbi:10090">mouse</span>
###xml 1195 1208 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1212 1218 <span type="species:ncbi:9606">humans</span>
###xml 1225 1230 <span type="species:ncbi:10090">mouse</span>
###xml 1268 1273 <span type="species:ncbi:9606">human</span>
###xml 1287 1292 <span type="species:ncbi:9606">human</span>
###xml 1368 1373 <span type="species:ncbi:10090">mouse</span>
###xml 1431 1437 <span type="species:ncbi:9606">humans</span>
###xml 1525 1530 <span type="species:ncbi:10090">mouse</span>
###xml 1625 1630 <span type="species:ncbi:9606">human</span>
These unique Abs allowed us to show a specific mechanism of action in vivo, in experiments using mice transgenic for human FcgammaRI. Such in vivo experiments are not possible in humans with P. falciparum malaria. Hence, recombinant human Abs engineered as described will be useful in correlating particular epitopes on MSP119 with protective immunity, as an aid to vaccine design, and will form the bases of effective in vivo assays prior to clinical trials in humans. Until now, work on human malaria parasites has made use of polyclonal Abs purified from immune sera in neutralization tests in vitro [18,19]. These antibody-dependent cellular inhibition experiments are technically demanding and far from optimal since sera contain a mixture of Abs, some with inappropriate specificities (such as blocking Abs) and the potential to trigger inhibitory FcR through intracellular immunoreceptor tyrosine inhibition motif signaling. The recombinant antibodies described herein are of a defined class and specificity and offer reproducible standards for such assays in an in vivo system, a model that has hitherto not been possible. The P. berghei mouse transgenic combination is a good model for P. falciparum in humans since mouse IgG2a binds with similar affinity to human monocytes as human IgG1, indicating that the transgenic receptor would be fully occupied with mouse IgG2a in vivo and accurately reflecting the situation in humans with IgG1 [28]. We believe that because of the obvious limitations to primate and SCID mouse studies, the transgenic approach described here is the best current model in which to address human antibody efficacy and function.
###end p 30
###begin p 31
###xml 475 477 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b029">29</xref>
###xml 478 480 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b030">30</xref>
###xml 550 563 542 555 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 647 649 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b018">18</xref>
###xml 978 979 950 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b004">4</xref>
###xml 980 981 952 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b005">5</xref>
###xml 1158 1160 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b031">31</xref>
###xml 1313 1332 1277 1296 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium chabaudi</named-content>
###xml 1374 1376 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b032">32</xref>
###xml 1952 1954 1908 1910 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 2180 2182 2128 2130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b033">33</xref>
###xml 247 262 <span type="species:ncbi:10090">transgenic mice</span>
###xml 550 563 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1273 1277 <span type="species:ncbi:10090">mice</span>
###xml 1313 1332 <span type="species:ncbi:5825">Plasmodium chabaudi</span>
###xml 1439 1444 <span type="species:ncbi:9606">human</span>
###xml 1874 1879 <span type="species:ncbi:9606">human</span>
###xml 1955 1960 <span type="species:ncbi:9606">human</span>
Although Abs (in particular of the IgG1 and IgG3 classes) from clinically immune individuals are without question involved in immunity to malaria, the role of their cognate FcRs has been investigated less thoroughly. FcgammaRI expression in these transgenic mice is limited to cells of the myeloid lineage, including monocytes and dendritic cells and can be upregulated by several cytokines including IL-10 and IFN-gamma, both of which are implicated in immunity to malaria [29,30]. Previous work has highlighted monocytes in Ab-dependent killing of P. falciparum asexual blood stages and implicated the involvement of FcgammaRII and FcgammaRIII [18]. From a therapeutic bioavailability standpoint triggering FcgammaRII may not be ideal. This is because both IgG1 and IgG3 can bind FcgammaRs on cells that do not directly kill parasites, including platelets, B cells, endothelial cells, and even placental tissue, resulting in the triggering of inhibitory FcgammaRII receptors [4,5]. This might benefit the parasite, analogous to the effect on tumor cell growth, in which passively administered anti-tumor Abs enhanced tumor cell growth through FcgammaRIIb [31]. That this is indeed the case for malaria has recently been shown in an elegant study in FcgammaRIIb-deficient mice, which have increased clearance of Plasmodium chabaudi malaria and develop less severe disease [32]. The same study went on to show that polymorphic variants of human FcgammaRIIb resulting in loss-of-function are common in African individuals who also show enhanced phagocytosis of parasites. Unfortunately, this study used pooled immune serum and whole parasites, and the contribution of individual IgG subclasses and the antigens driving FcgammaRIIb signaling could not be investigated. The epitope-specific reagents described in this study would allow these questions to be answered for fully human antibodies. For example, we are in the process of mutating our anti-MSP119 human IgG1s to make more potent antimalarial antibodies by changing residues in the Fc that optimize binding to the activatory receptors, including FcgammaRI, at the expense of binding to the FcgammaRIIb inhibitory receptor [33].
###end p 31
###begin p 32
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b034">34</xref>
###xml 212 228 204 220 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Candida albicans</named-content>
###xml 304 306 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b035">35</xref>
###xml 307 309 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b036">36</xref>
###xml 577 585 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0030072-g007">Figure 7</xref>
###xml 212 228 <span type="species:ncbi:5476">Candida albicans</span>
Merozoite killing can also be mediated by neutrophils [present study and 24,34]. Neutrophils are the most populous leucocyte in blood and can express FcgammaRI on activation with IFN-gamma or G-CSF and targeting Candida albicans toward neutrophil FcgammaRI results in potent fungicidal activity in vivo [35,36]. However, we do not observe any increase in expression of the FcgammaRI transgene on neutrophils from animals infected with malaria parasites and therefore conclude that protective immunity manifested by this IgG1 is mediated through monocytes (unpublished data and Figure 7).
###end p 32
###begin p 33
###xml 143 145 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b017">17</xref>
###xml 436 438 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b037">37</xref>
###xml 439 441 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b038">38</xref>
###xml 635 637 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b039">39</xref>
###xml 168 173 <span type="species:ncbi:9606">human</span>
It is known that the alpha-chain of FcgammaRI can mediate protective signaling events either through the common alpha-chain or via Periplakin [17]. The availability of human FcgammaRI-transgenic animals deficient in Periplakin will permit the delineation of which signaling pathway is important in protection to malaria. FcgammaRI represents the only FcgammaR with a well-documented capacity to facilitate immunological memory in vivo [37,38]. This may be crucial in the context of malaria where the inability to induce or maintain long-term memory responses is likely to pose major problems for the development of effective vaccines [39].
###end p 33
###begin p 34
###xml 200 202 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b040">40</xref>
###xml 955 957 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b032">32</xref>
###xml 958 960 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b041">41</xref>
###xml 961 963 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b043">43</xref>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 1013 1018 <span type="species:ncbi:9606">human</span>
###xml 1048 1052 <span type="species:ncbi:10090">mice</span>
###xml 1074 1079 <span type="species:ncbi:9606">human</span>
Although no crystal structure exists for the interaction of human FcgammaRI with IgG1, the location has been inferred by comparison with known structures for the association of IgG1 with FcgammaRIII [40]. Such analyses consistently highlight an extended hydrophobic area formed at the interface between the two N-terminal domains with contacting residues within the D1/D2 connector, the B/C, C/E, and F/G loops of the EC2 domain. This region shows great variability between the membrane-anchored version of FcgammaRI, encoded by FcgammaRIa, and the FcgammaRIb and FcgammaRIc genes which are predicted to encode secreted forms that suggest differences in ability to bind IgG1. The role of these variant genes in malaria is unknown. Although polymorphisms in FcgammaRIIa, FcgammaRIIIb, and more recently FcgammaRIIb, have been implicated in susceptibility to severe malaria, no associations with FcgammaRIa, or its associating subunits, have yet been made [32,41-43]. It will be important to determine if our fully human IgG1s are also protective in mice transgenic for other human FcgammaRs, including FcgammaRIIa.
###end p 34
###begin p 35
###xml 325 338 321 334 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 234 239 <span type="species:ncbi:9606">human</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 325 338 <span type="species:ncbi:5833">P. falciparum</span>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
By searching single nucleotide polymorphism () and trace databases, we identified FcgammaRIa-specific polymorphic residues both in this region of EC2 and in the cytoplasmic signaling domain that might affect the outcome of malaria in human populations. By creating mice transgenic for these variants, our humanized model for P. falciparum malaria provides an opportunity for testing experimentally and in vivo the effect of these polymorphisms on the efficacy of antibody function in relation to malaria. The ability to predict how antibodies will work in groups of patients with particular FcgammaR polymorphisms would allow targeted and tailored therapy for these expensive reagents.
###end p 35
###begin p 36
###xml 174 176 170 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 546 547 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b002">2</xref>
###xml 548 550 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b044">44</xref>
###xml 159 164 <span type="species:ncbi:9606">human</span>
###xml 278 284 <span type="species:ncbi:9606">humans</span>
###xml 525 533 <span type="species:ncbi:9606">children</span>
A clearer understanding of the role for individual FcgammaRs in malaria immunity is vital if Abs are to be used successfully as therapeutic entities. Although human anti-MSP119 IgG1 is clearly effective in passive immunization, its usefulness remains to be tested in rodents or humans with already well-established parasitemias. That they have the potential to be extremely useful in such settings is supported by proof-of-principle studies showing that passive transfer of polyclonal IgG can reduce existing parasitemias in children and adults [2,44].
###end p 36
###begin p 37
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b004">4</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b005">5</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b045">45</xref>
###xml 429 431 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b046">46</xref>
###xml 660 662 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b047">47</xref>
###xml 758 760 750 752 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 836 839 828 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">235</sup>
###xml 844 847 836 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">329</sup>
###xml 856 859 848 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">328</sup>
###xml 969 971 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b040">40</xref>
###xml 58 64 <span type="species:ncbi:9606">humans</span>
###xml 451 457 <span type="species:ncbi:9606">humans</span>
###xml 603 610 <span type="species:ncbi:9606">infants</span>
###xml 631 658 <span type="species:ncbi:12814">respiratory syncytial virus</span>
A potential drawback to using IgG1 for malaria therapy in humans is the high level of nonspecific IgG1 in the hypogammaglobulinemia induced shortly after infection [4,5,45]. Such Abs might compete with passively administered IgG1 for FcgammaRI occupancy, and therefore phagocyte recruitment. The presence of pre-existing IgG may explain why large doses of Ab have been required to neutralize parasites both in vitro and in vivo [46]. Extrapolating to humans, the effective dose of 0.75 mg/animal seen with JS1 compares well with the required dosage of Palivizumab (15-75 mg/kg) known to protect at-risk infants from infection with respiratory syncytial virus [47]. A potential solution would be to engineer increased affinity for FcgammaRI into our anti-MSP119 IgG1, for example, by introducing more hydrophobic residues in place of Leu235, Pro329, and Leu328 that would bind to FcgammaRI in preference to pre-existing IgGs, thus facilitating the use of lower dosages [40].
###end p 37
###begin p 38
Given increasing problems with resistance to antimalarial drugs, a vaccine against malaria has become the ultimate goal. Unfortunately, its development has been beset with problems, and alternative strategies to treat malaria are urgently sought. Here we have shown that the passive delivery of recombinant Abs should be considered important adjuncts to more traditional vaccine approaches, since Abs have the potential to act both as therapies and as vehicles for the optimal delivery of antigens in vaccination.
###end p 38
###begin title 39
Materials and Methods
###end title 39
###begin title 40
Phage libraries and selection procedures.
###end title 40
###begin p 41
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b048">48</xref>
###xml 905 910 905 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 1062 1064 1062 1064 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b049">49</xref>
###xml 1095 1097 1095 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1466 1482 1459 1475 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Escherichia coli</named-content>
###xml 1624 1626 1617 1619 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1787 1800 1780 1793 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 1877 1879 1870 1872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b021">21</xref>
###xml 1880 1882 1873 1875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 1466 1482 <span type="species:ncbi:562">Escherichia coli</span>
###xml 1787 1800 <span type="species:ncbi:5833">P. falciparum</span>
Two phage-display combinatorial immune antibody libraries were created from peripheral blood mononuclear leucocytes derived from 20 Gambian donors during the dry season (March 1997 library, low prevalence of clinical malaria) or at the end of the wet season (October 1997 library, high prevalence of clinical malaria). For this study, informed consent was obtained with guidelines of the Gambian Ministry of Health and the Medical Research Council, whose ethical review committees approved all protocols. From these, ten donors were selected at random on the basis of previously noted high levels of anti-MSP1 IgG for library construction. The scFv libraries were constructed using standard sets of primers from pooled total RNA obtained from peripheral blood monocytes as described [20,48]. scFvs from the heavy- and light-chain repertoires were cloned sequentially into pHEN1H6 upstream of hexa-HIS and c-myc tags via SfiI/NotI restriction sites. The phage libraries were panned for binders using immunotubes (Nunc, Maxisorp, ) and coated with recombinant MSP119-GST [49]. Approximately 1 x 1014 phage from each of the two libraries were blocked in PBS containing 18% (w/v) skimmed milk powder and 100 mug/ml GST to prevent selection of anti-GST scFvs during panning, prior to addition to the coated immunotubes at 37 degreesC for 1 h. Bound phage were eluted into 100 mM triethylamine (pH 11.0), neutralized with 1 M Tris-HCl (pH 7.4), and then allowed to infect Escherichia coli TG1 host cells for amplification. After three further rounds of binding and amplification, 96 single clones were screened for binding to MSP119 by: (a) direct ELISAs, (b) competition ELISAs with mAb 12.8 and 12.10, known to be potent inhibitors of erythrocyte invasion in vitro, (c) IFA to acetone-fixed P. falciparum-infected erythrocytes, and (d) immunoblotting, all as described previously [21-24].
###end p 41
###begin title 42
###xml 16 21 <span type="species:ncbi:9606">human</span>
Construction of human antibodies.
###end title 42
###begin p 43
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 114 120 114 120 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCGCGC</underline>
###xml 169 176 169 176 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTGACC</underline>
###xml 301 302 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sub>
###xml 367 373 363 369 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GTGCAC</underline>
###xml 412 418 408 414 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GTGCAC</underline>
###xml 471 477 467 473 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTCGAG</underline>
###xml 576 578 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 579 581 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b050">50</xref>
###xml 723 725 715 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 864 866 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 558 563 <span type="species:ncbi:9606">human</span>
###xml 584 599 <span type="species:ncbi:10029">Chinese hamster</span>
###xml 782 786 <span type="species:ncbi:9925">goat</span>
###xml 792 797 <span type="species:ncbi:9606">human</span>
###xml 816 827 <span type="species:ncbi:3704">horseradish</span>
###xml 879 884 <span type="species:ncbi:9606">human</span>
###xml 1015 1020 <span type="species:ncbi:9606">human</span>
The VH genes derived from scFv clones c1 and e9 were amplified by PCR using the following pairs of forward (5'ACAGGCGCGCACTCCGAGGTGCAGCTG-3') and reverse (5'ACCTGAGGAGACGGTGACCAGGGT-3') primers and subcloned as BssHII/BstEII fragments into pVHExpress vectors, upstream of the gamma1 constant region. VL genes were amplified using sequence specific forward (c1, 5'-GGCGTGCACTCCGATATTGTGATGACCCAG-3' and e9, 5'-GGCGTGCACTCCGATGTTGTGATGACTCAG-3') and reverse primers (5'-GATCTCGAGACTCACGTTTGATCTCCA-3') as an ApaLI/XhoI fragment into pVKExpress upstream of the human kappa gene [24,50]. Chinese hamster ovary (CHO)-K1 cells were transfected with corresponding heavy- and light-chain plasmids and positive clones secreting MSP119-specific IgG1 detected by ELISA or immunoblotting using goat anti-human IgG conjugated to horseradish peroxidase as described previously [24]. Two fully human antibodies were produced, JS1 and JS2, derived from scFvs c1 and e9, respectively. From large-scale cultures of both JS1 and JS2, human IgG1 was purified on HiTrap protein G-Sepharose (GE Healthcare, ) by FPLC. The integrity and purity of the antibodies was verified on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels.
###end p 43
###begin title 44
Antigen binding and invasion-inhibitory assays.
###end title 44
###begin p 45
###xml 135 137 135 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 413 418 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-myc</italic>
###xml 656 658 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 786 799 777 790 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 952 954 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 1348 1350 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 1580 1593 1570 1583 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 1601 1611 1591 1601 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 1627 1640 1617 1630 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 1645 1647 1635 1637 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1690 1692 1680 1682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 1693 1695 1683 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 1696 1698 1686 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b025">25</xref>
###xml 1794 1796 1784 1786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b021">21</xref>
###xml 561 565 <span type="species:ncbi:9925">goat</span>
###xml 571 576 <span type="species:ncbi:10090">mouse</span>
###xml 786 799 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1241 1245 <span type="species:ncbi:9925">goat</span>
###xml 1251 1256 <span type="species:ncbi:10090">mouse</span>
###xml 1580 1593 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1601 1611 <span type="species:ncbi:5821">P. berghei</span>
###xml 1627 1640 <span type="species:ncbi:5833">P. falciparum</span>
For direct ELISAs, scFv supernatants from individual clones were added to wells of a microtiter plate (Nunc, Maxisorp) coated with MSP119-GST (diluted to 1 mug/ml in coating buffer) after incubation in blocking solution (phosphate buffered saline/3% milk powder). The scFvs were allowed to bind for 1 h at 37 degreesC before three washes in PBS/0.1% Tween-20 and three further washes in PBS. 100 mul of 9E10 anti-c-myc hybridoma supernatant was added to each well. After 1 h the plate was washed as above and 100 mul of a 1/5,000 dilution peroxidase-conjugated goat anti-mouse antibody (Jackson ImmunoResearch Laboratory, ) in blocking solution was added [20]. After 1 h the plate was washed as before and developed with Neogen K-BLUE substrate (). For western blotting, T9/96 or FCB-1 P. falciparum merozoites were boiled in nonreducing sample buffer and extracts loaded into wells of a 15% SDS-PAGE gel prior to transfer to nitrocellulose membranes [20]. The membrane was incubated in blocking solution for 2 h before adding polyclonal scFv at 1 mug/ml for 1 h. The membrane was washed three times with PBS/0.1% Tween-20 and then incubated with 9E10 supernatant for 1 h on a rotating platform. A 1:25,000 dilution of peroxidase-conjugated goat anti-mouse antibody in blocking solution was added and incubated for 1 h followed by washes as above [20]. Membranes were developed using ECL chemiluminescent detection system (GE Healthcare). Selected Ni-NTA purified or polyclonal scFvs and intact antibodies were tested for their ability to bind acetone-fixed T9/96, FCB-1, and 3D7 P. falciparum or the P. berghei transgenic for P. falciparum MSP119 (PbPfM19) by IFA as described previously [20,24,25]. Invasion and processing assays were carried out according to previously published protocols [21].
###end p 45
###begin title 46
Epitope mapping.
###end title 46
###begin p 47
###xml 257 259 257 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 493 495 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 626 628 624 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 745 747 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b026">26</xref>
###xml 897 899 895 897 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1212 1214 1210 1212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 792 797 <span type="species:ncbi:9606">human</span>
A number of approaches were used to map the antigenic structures recognized by the V genes cloned from scFvs c1 and e9. A competition ELISA was designed to determine if scFvs or intact Abs could compete with mAbs 12.8 and 12.10 for binding sites on the MSP119 molecule. After coating in pre-blocked scFv or JS1/JS2 and washed as above, mAb 12.8 or 12.10 (0.5 mug and 0.05 mug/ml, respectively) diluted in blocking solution were allowed to bind. Bound mAb was then detected as described above [20]. A second approach, combining ELISAs, western blotting, and SPR analysis took advantage of an extensive panel of recombinant MSP119 mutants derived by site-directed mutagenesis and used in an earlier study to map both inhibitory and blocking mAbs [26]. For a quantitative comparison of binding, human IgG1s (JS1 or JS2) were amine-coupled to each flow cell of a CM5 sensor chip. 2,500 nM of each MSP119 mutant was then injected over each antibody and association and dissociation observed. Data from a BIAcore X machine were analyzed using BIAevaluation 3.0 software. Antibody binding to the panel of mutants was scored as follows: "++" indicates approximately the same amount of antibody binding to the mutant MSP119 as to wild-type, "+" indicates reduced binding to the mutant compared to wild-type, and "-" indicates no detectable antibody binding to the mutant protein.
###end p 47
###begin title 48
Respiratory burst and phagocytosis assays.
###end title 48
###begin p 49
###xml 113 115 113 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 119 121 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 134 136 133 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 162 164 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 277 279 275 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 283 285 281 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 405 406 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 563 564 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 611 613 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
A chemiluminescence-based neutrophil respiratory burst assay was conducted on plates coated with recombinant GST-PfMSP119 at 10 mug mL-1 as previously described [24]. 1 mum red fluorescent carboxylate-modified microspheres (Molecular Probes, ) were covalently coupled with GST-PfMSP119 using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, hydrochloride (EDAC) as per manufacturer's instructions. 7.2 x 104 beads were coated with 100 mug/ml of each antibody in PBS/10% FCS. After three washes, beads were resuspended in a final volume of 100 mul containing 5 x 104 neutrophils purified as previously described [24]. Cells and beads were gently pelleted at 1,200 rpm and incubated for 30 min at 37 degreesC. Cells were then gently resuspended and smeared onto glass slides and allowed to dry prior to mounting in ProLong Gold antifade reagent with DAPI (Invitrogen, ). Phagocytosis was observed by immunofluorescence microscopy (Zeiss Axioskop 40, ).
###end p 49
###begin title 50
Passive immunization and parasite challenge.
###end title 50
###begin p 51
###xml 43 57 43 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P. falciparum,</italic>
###xml 197 199 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b029">29</xref>
###xml 920 930 903 913 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 956 969 939 952 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 974 976 957 959 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 1068 1070 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 1071 1073 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b025">25</xref>
###xml 1250 1252 1233 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 43 56 <span type="species:ncbi:5833">P. falciparum</span>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 74 89 <span type="species:ncbi:10090">transgenic mice</span>
###xml 189 195 <span type="species:ncbi:9606">humans</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 351 355 <span type="species:ncbi:10090">Mice</span>
###xml 512 517 <span type="species:ncbi:9606">human</span>
###xml 600 605 <span type="species:ncbi:9606">human</span>
###xml 872 877 <span type="species:ncbi:10090">mouse</span>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
###xml 920 930 <span type="species:ncbi:5821">P. berghei</span>
###xml 956 969 <span type="species:ncbi:5833">P. falciparum</span>
Because of the lack of an animal model for P. falciparum, human FcgammaRI transgenic mice have been developed that exhibit similar FcgammaRI cell distribution and expression patterns as in humans [29]. Tg Balb/c x Balb/c F1 mice 9- to 12-wk-old and bred under specific pathogen-free conditions were used. Nontransgenic littermates served as controls. Mice were screened for FcgammaRI expression by PCR of whole blood using forward (5' AGATTTCACTGCTCCCACCA-3') and reverse (5' CACTTGCCCATCAACTGGA-3') primers for human CD64 and by analysis of lysed whole blood on a FAC-Scan with FITC-conjugated anti-human FcgammaRI (unpublished data). Antibodies (0.25 or 0.5 mg/injection depending on experiment) or blocking mAb 10.1 (at 50 mug/injection, Serotec, ) were administered i.p. on day -1, day 0, and day +1 with respect to parasite challenge. Parasitized erythrocytes (5,000/mouse) derived from passaged mice infected with P. berghei parasites transgenic for P. falciparum MSP119 were injected i.p. at least 3 h after antibody treatment on day 0 as previously described [24,25]. Parasitemia was assessed daily on Giemsa reagent-stained blood smears. Differences between groups were analyzed over two replicate experiments using the Mann Whitney test. A p-value < 0.01 was considered significant. All animal experiments were approved by the Home Office and performed in accordance with United Kingdom guidelines and regulations (PPL40/2753).
###end p 51
###begin p 52
###xml 637 639 637 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 244 248 <span type="species:ncbi:163112">Ling</span>
###xml 461 467 <span type="species:ncbi:9606">people</span>
This paper is dedicated to the late Dr. Jonathan Chappel. We thank Eilish Cullen, Olivier Leger, Alison Levy, Margaret Cronin, Keith Ansell, and Katy Kettleborough in the Medical Research Council Collaborative Centre (MRC Technology) and Irene Ling, Muni Grainger, and Terry Scott-Finnigan in the Division of Parasitology at the National Institute for Medical Research. We would especially like to thank Margaret Pinder, Bolong Jaiteh, Momodou Sanyang, and the people of the village of Brefet in the Gambia for their assistance in enabling us to obtain blood donations. We thank Dr. Karen Bunting for help with molecular modeling of MSP119 and Dr. Phil Buckle at Biacore for elucidation of affinity data. We thank the Medical Research Council and the European Union for supporting our work.
###end p 52
###begin title 53
Abbreviations
###end title 53
###begin p 54
antibody
###end p 54
###begin p 55
Fc receptor
###end p 55
###begin p 56
immunofluorescence
###end p 56
###begin p 57
immunoglobulin
###end p 57
###begin p 58
intraperitoneally
###end p 58
###begin p 59
monoclonal Ab
###end p 59
###begin p 60
merozoite surface protein 1
###end p 60
###begin p 61
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium berghei</italic>
###xml 44 65 44 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium falciparum</italic>
###xml 70 72 70 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 0 18 <span type="species:ncbi:5821">Plasmodium berghei</span>
###xml 44 65 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium berghei parasites transgenic for Plasmodium falciparum MSP119
###end p 61
###begin p 62
surface plasmon resonance
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
###xml 48 69 48 69 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 48 69 <span type="species:ncbi:5833">Plasmodium falciparum</span>
The global distribution of clinical episodes of Plasmodium falciparum malaria
###end article-title 64
###begin article-title 65
###xml 40 45 <span type="species:ncbi:9606">human</span>
Gamma-globulin and acquired immunity to human malaria
###end article-title 65
###begin article-title 66
Pathways and strategies for developing a malaria blood-stage vaccine
###end article-title 66
###begin article-title 67
Antibody-based therapies for malaria
###end article-title 67
###begin article-title 68
Antibody and Fc-receptor-based therapeutics for malaria
###end article-title 68
###begin article-title 69
###xml 59 61 59 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 87 97 87 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium</italic>
Functional conservation of the malaria vaccine antigen MSP119 across distantly related Plasmodium species
###end article-title 69
###begin article-title 70
###xml 24 45 24 45 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 24 45 <span type="species:ncbi:5833">Plasmodium falciparum</span>
A proteomic view of the Plasmodium falciparum life cycle
###end article-title 70
###begin article-title 71
###xml 50 52 50 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
Antibodies against merozoite surface protein (MSP119) are a major component of the invasion-inhibitory response in individuals immune to malaria
###end article-title 71
###begin article-title 72
A genetic approach to the de novo identification of targets of strain-specific immunity in malaria parasites
###end article-title 72
###begin article-title 73
###xml 110 128 110 128 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium berghei</named-content>
###xml 110 128 <span type="species:ncbi:5821">Plasmodium berghei</span>
A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood stage Plasmodium berghei XAT infection
###end article-title 73
###begin article-title 74
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
Fc receptors are not required for Ab-mediated protection against lethal malaria challenge in a mouse model
###end article-title 74
###begin article-title 75
###xml 26 49 26 49 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Cryptococcus neoformans</named-content>
###xml 26 38 <span type="species:ncbi:89924">Cryptococcus</span>
###xml 26 49 <span type="species:ncbi:5207">Cryptococcus neoformans</span>
Ab-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses
###end article-title 75
###begin article-title 76
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
Identification of the mouse IgG3 receptor: Implications for Ab effector function at the interface between innate and adaptive immunity
###end article-title 76
###begin article-title 77
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection
###end article-title 77
###begin article-title 78
###xml 20 24 <span type="species:ncbi:10090">mice</span>
FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses
###end article-title 78
###begin article-title 79
The FcgammaRIa (CD64) ligand-binding chain triggers major histocompatibility complex class II Ag presentation independently of its associated FcR gamma-chain
###end article-title 79
###begin article-title 80
Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand-binding capacity
###end article-title 80
###begin article-title 81
###xml 68 89 68 89 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 68 89 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Mechanisms underlying the monocyte-mediated Ab-dependent killing of Plasmodium falciparum asexual blood stages
###end article-title 81
###begin article-title 82
###xml 39 60 39 60 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 24 30 <span type="species:ncbi:9606">humans</span>
###xml 39 60 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes
###end article-title 82
###begin article-title 83
A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibitory antibodies
###end article-title 83
###begin article-title 84
###xml 123 128 <span type="species:ncbi:9606">human</span>
Abs that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human Abs
###end article-title 84
###begin article-title 85
Novel antimalarial Abs highlight the importance of the Ab Fc region in mediating protection
###end article-title 85
###begin article-title 86
###xml 53 74 53 74 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 110 112 110 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 53 74 <span type="species:ncbi:5833">Plasmodium falciparum</span>
A new rodent model to assess blood stage immunity to Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies
###end article-title 86
###begin article-title 87
###xml 102 123 102 123 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 102 123 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Inhibitory and blocking monoclonal Ab epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum
###end article-title 87
###begin article-title 88
###xml 37 58 37 58 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 37 58 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties
###end article-title 88
###begin article-title 89
###xml 47 52 <span type="species:ncbi:9606">human</span>
Localization of the monocyte-binding region on human immunoglobulin G
###end article-title 89
###begin article-title 90
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 99 114 <span type="species:ncbi:10090">transgenic mice</span>
Antigen targeting to myeloid-specific human FcgammaR1/CD64 triggers enhanced antibody responses in transgenic mice
###end article-title 90
###begin article-title 91
Clinical significance of IgG Fc receptors and FcgammaR directed therapies
###end article-title 91
###begin article-title 92
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
###end article-title 92
###begin article-title 93
Systemic lupus erythrematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria
###end article-title 93
###begin article-title 94
Engineered antibody Fc variants with enhanced effector function
###end article-title 94
###begin article-title 95
###xml 104 125 104 125 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 104 125 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Effects of cytokines, complement, and Ab on the neutrophil respiratory burst and phagocytic response to Plasmodium falciparum merozoites
###end article-title 95
###begin article-title 96
###xml 113 118 <span type="species:ncbi:9606">human</span>
Neutrophils express the high affinity receptor for IgG (FcgammaR1,CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor
###end article-title 96
###begin article-title 97
###xml 61 72 57 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Candidiasis</italic>
Neutrophil FcgammaR1 as target for immunotherapy of invasive Candidiasis
###end article-title 97
###begin article-title 98
Therapeutic efficacy of FcgammaR1/CD64-directed bispecific antibodies in B-cell lymphoma
###end article-title 98
###begin article-title 99
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 79 94 <span type="species:ncbi:10090">transgenic mice</span>
Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice
###end article-title 99
###begin article-title 100
Does malaria suffer from lack of memory?
###end article-title 100
###begin article-title 101
Molecular basis for immune complex recognition: A comparison of Fc-receptor structures
###end article-title 101
###begin article-title 102
###xml 103 124 103 124 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 74 81 <span type="species:ncbi:9606">infants</span>
###xml 103 124 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection. VII. Asembo Bay Cohort Project
###end article-title 102
###begin article-title 103
Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa
###end article-title 103
###begin article-title 104
Fcgamma receptor IIA and IIIB polymorphisms are associated with susceptibility to cerebral malaria
###end article-title 104
###begin article-title 105
###xml 39 60 39 60 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 24 30 <span type="species:ncbi:9606">humans</span>
###xml 39 60 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes
###end article-title 105
###begin article-title 106
###xml 109 112 <span type="species:ncbi:9606">man</span>
Alterations in serum proteins and 19S antibody production during the course of induced malarial infection in man
###end article-title 106
###begin article-title 107
###xml 33 54 33 54 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 33 54 <span type="species:ncbi:5833">Plasmodium falciparum</span>
A robust neutralization test for Plasmodium falciparum malaria
###end article-title 107
###begin article-title 108
###xml 51 54 <span type="species:ncbi:12814?0.7497633322814768">RSV</span>
###xml 105 108 <span type="species:ncbi:12814?0.7497633322814768">RSV</span>
Revised indications for the use of Palivizumab and RSV immune globulin intravenous for the prevention of RSV infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
###end article-title 108
###begin article-title 109
###xml 25 30 <span type="species:ncbi:9606">Human</span>
By-passing immunization. Human antibodies from V-gene libraries displayed on phage
###end article-title 109
###begin article-title 110
###xml 58 79 58 79 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Plasmodium falciparum</named-content>
###xml 111 127 111 127 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Escherichia coli</named-content>
###xml 58 79 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 111 127 <span type="species:ncbi:562">Escherichia coli</span>
Expression of the 19-kDa carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein
###end article-title 110
###begin article-title 111
An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries
###end article-title 111
###begin title 112
Figures and Tables
###end title 112
###begin title 113
Characterization of scFvs Derived from Phage Libraries
###end title 113
###begin p 114
Estimation of diversity of library scFv inserts by BstNI digestion. Figure shows restriction digest patterns of 50 randomly selected scFvs from the October library.
###end p 114
###begin p 115
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</sub>
(A) 50 inserts of the VH-VK scFvs amplified by PCR screen from 50 randomly selected colonies.
###end p 115
###begin p 116
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</sub>
(B) The same VH-VK scFv inserts after digestion with BstNI. A large number of different digestion patterns are seen, suggesting a high degree of diversity among the library.
###end p 116
###begin p 117
###xml 60 73 60 73 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 208 221 208 221 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 236 238 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 436 449 435 448 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 492 494 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
###xml 780 782 779 781 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 863 865 862 864 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">33</sub>
###xml 897 899 896 898 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">83</sub>
###xml 930 932 929 931 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">42</sub>
###xml 941 943 940 942 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 60 73 <span type="species:ncbi:5833">P. falciparum</span>
###xml 208 221 <span type="species:ncbi:5833">P. falciparum</span>
###xml 436 449 <span type="species:ncbi:5833">P. falciparum</span>
(C-E) Binding of polyclonal scFv from panning rounds 1-4 to P. falciparum by IFA [20]. IFA was carried out using acetone-fixed parasites, and the polyclonal scFv tested against the T9-96 and FCB-1 strains of P. falciparum at 20 mug/ml [20]. MAb 12.8 was used as a positive control and polyclonal scFv prepared from the unpanned libraries used as negative controls. Immunoblots of polyclonal scFv from fourth round of panning binding to P. falciparum strain T9/96 (D) or FCB-1 (E) merozoites [20]. Lane 1, scFv March library unpanned; lane 2, scFv October library unpanned; lane 3-6, scFv from fourth round of panning with unprocessed merozoites; lane 7-8, scFv from fourth round of panning with processed merozoites; lane 9, scFv from fourth round of panning with recombinant MSP119-GST; lane 10, scFv D1.3 (anti-hen's egg lysozyme); lane 11, scFv X509 (anti-MSP133); lane 12, scFv 89.1 (anti-MSP183); lane 13, mAb 12.8 (anti-MSP142 and MSP119).
###end p 117
###begin p 118
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b020">20</xref>
(F) Inhibition of binding of mAbs 12.8 and 12.10 to MSP119 by scFvs derived from the fourth round of panning by competition ELISA [20].
###end p 118
###begin title 119
Sequencing of V Genes and SPR Analysis
###end title 119
###begin p 120
###xml 32 34 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 147 149 147 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 158 171 158 171 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 158 171 <span type="species:ncbi:5833">P. falciparum</span>
(A) Amino acid sequences of MSP119-binding scFvs. Sequences of six selected scFvs obtained by panning phage display libraries with recombinant MSP119 (C1) or P. falciparum merozoites in which secondary processing had been allowed to proceed (E9). Amino acids in bold represent residues in the E9 sequence differing to C1.
###end p 120
###begin p 121
###xml 65 67 65 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
(B) SPR association and dissociation curves of Ab binding to MSP119 immobilized on a CM5 sensor chip. Abs were injected into flow at time 0 and replaced with buffer at the point indicated by vertical arrow [24].
###end p 121
###begin title 122
Characterization of Purified Abs
###end title 122
###begin p 123
###xml 28 30 27 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 228 233 <span type="species:ncbi:9606">human</span>
(A) 5 mug purified anti-MSP119 human IgG1 (JS1) was subjected to SDS-PAGE under nonreducing (lane 1) or reducing (lane 2) conditions on 4%-15% polyacrylamide gradient gels and stained with Simply Blue or immunoblotted with anti-human IgG-HRP.
###end p 123
###begin p 124
###xml 90 92 90 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 136 138 136 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 223 225 223 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 75 80 <span type="species:ncbi:9606">human</span>
(B) Under nonreducing conditions and after transfer to nitrocellulose, the human anti-MSP119 IgG1 (JS1) detects the recombinant GST-MSP119 fusion protein (lane 3) but not the GST alone control (lane 4). Localization of MSP119 by IFA.
###end p 124
###begin p 125
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 140 146 <span type="species:ncbi:9986">rabbit</span>
###xml 216 220 <span type="species:ncbi:9925">goat</span>
###xml 226 232 <span type="species:ncbi:9986">rabbit</span>
###xml 288 293 <span type="species:ncbi:9606">human</span>
(C) Schizont- and merozoite-stage parasites from the transgenic PbPbM19 and PbPfM19 lines were incubated with human Abs JS1 or JS2 (1:100), rabbit alphaPbM19 (1:1,000), or alphaPfM19 (1:1,000). After incubation with goat anti-rabbit Alexa-conjugated Ig (1:1,000) and FITC-conjugated anti-human IgG Fc (1:200), slides were washed and mounted in Vectrashield anti-fade. Parasites were visualized by fluorescence microscopy x100 magnification, with the same fields photographed using filters to detect Alexa and FITC.
###end p 125
###begin p 126
###xml 26 28 26 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 107 120 107 120 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 269 271 269 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 277 286 277 286 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. yoelii</named-content>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0030072-b024">24</xref>
###xml 107 120 <span type="species:ncbi:5833">P. falciparum</span>
###xml 236 241 <span type="species:ncbi:9606">human</span>
###xml 277 286 <span type="species:ncbi:5861">P. yoelii</span>
(D) JS1 reactive with MSP119 on methanol-acetone-fixed smears of merozoites and erythrocytes infected with P. falciparum (strain 3D7) x40 magnification. JS2 gave similar results. No specific fluorescence was detected with an irrelevant human IgG1 (B10) recognizing MSP119 from P. yoelii [24].
###end p 126
###begin title 127
###xml 33 38 <span type="species:ncbi:9606">Human</span>
JS1 and JS2 Are Fully Functional Human Antibodies
###end title 127
###begin p 128
###xml 50 52 50 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 161 163 160 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 169 178 168 177 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. yoelii</named-content>
###xml 4 9 <span type="species:ncbi:9606">Human</span>
###xml 115 120 <span type="species:ncbi:9606">human</span>
###xml 169 178 <span type="species:ncbi:5861">P. yoelii</span>
(A) Human neutrophil-mediated phagocytosis of GST-PfMSP119 coated fluorescent 1-mum microspheres by JS1. A control human IgG1 recognizing the homologous GST-MSP119 from P. yoelii was unable to opsonize beads and no ingestion was observed. Phagocytosed beads (red) were visualized in the cytoplasm of neutrophils (arrowed) whose nuclear DNA was counterstained in blue by DAPI.
###end p 128
###begin p 129
###xml 91 93 91 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 179 181 179 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 185 187 185 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 303 305 277 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 188 193 <span type="species:ncbi:9606">human</span>
###xml 228 233 <span type="species:ncbi:9606">human</span>
(B) Stimulation of neutrophil NADPH oxidative bursts using JS1 and JS2 attached to GST-MSP119-coated microtiter plates. Chemiluminescence (CL; arbitary units) was induced by anti-PfMSP119 human IgG1 JS1 (open diamond), JS2 (o), human IgA1 (square), or no antibody (triangle up). All antibodies at 1 x 10-7 M. Data are presented as mean arbitary units from duplicate wells with neutrophils from a single donor.
###end p 129
###begin title 130
###xml 69 71 69 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 54 59 <span type="species:ncbi:9606">Human</span>
Inhibition of Binding of mAbs 12.10 and 12.8 by Fully Human Anti-MSP119 IgG1s (JS1 and JS2) by Competition ELISA
###end title 130
###begin p 131
The binding of 12.8 is reduced by over 60% and the binding by 12.10 reduced by 30% suggesting that JS1 and JS2 compete with mAbs 12.8 and 12.10 for similar or overlapping epitopes. mAb 12.8, JS1, and JS2 were used at 0.5 mug/ml and mAb 12.10 at 0.05 mug/ml. Similar results were also observed when saturating concentrations of antibodies were used.
###end p 131
###begin title 132
Epitope Mapping of JS1 and JS2 Binding Sites
###end title 132
###begin p 133
###xml 53 66 53 66 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 71 73 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 194 196 194 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sup>
###xml 313 315 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 426 428 426 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">20</sup>
###xml 436 438 436 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">33</sup>
###xml 583 590 583 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0030072-t001">Table 1</xref>
###xml 627 629 627 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40</sup>
###xml 634 636 634 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">29</sup>
###xml 645 647 645 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">39</sup>
###xml 747 760 747 760 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 765 767 765 767 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 53 66 <span type="species:ncbi:5833">P. falciparum</span>
###xml 366 372 <span type="species:ncbi:10090">murine</span>
###xml 747 760 <span type="species:ncbi:5833">P. falciparum</span>
Shows the location in the three-dimensional model of P. falciparum MSP119 of residues in the first epidermal growth factor domain, which on mutation affect binding by JS1 or JS2. Mutation of Cys28 shown in red completely ablated binding of both mAbs (12.10 and 12.8) and JS1 or JS2. Mutation of the partnering Cys12, also shown in red, while ablating binding by the murine mAbs, had no effect on the binding by JS1 or JS2. Arg20 and Asn33 in salmon had intermediate effects on binding as determined by SPR analysis when mutated to more neutral or negatively charged side-chains (see Table 1). Three further substitutions at Lys40, Lys29, and Asn39 seen in brown had minor effects on binding when the interaction was studied by ELISA. The model of P. falciparum MSP119 was generated by PyMol using atomic coordinates available from NCBI under accession number PDB: 1CEJ.
###end p 133
###begin title 134
###xml 12 25 12 25 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 30 32 30 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 44 54 44 54 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. berghei</named-content>
###xml 12 25 <span type="species:ncbi:5833">P. falciparum</span>
###xml 44 54 <span type="species:ncbi:5821">P. berghei</span>
###xml 68 72 <span type="species:ncbi:10090">Mice</span>
Course of a P. falciparum MSP119 Transgenic P. berghei Infection in Mice
###end title 134
###begin p 135
###xml 143 156 139 152 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 161 163 157 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 223 225 219 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 231 240 227 236 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. yoelii</named-content>
###xml 431 432 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 132 137 <span type="species:ncbi:9606">human</span>
###xml 143 156 <span type="species:ncbi:5833">P. falciparum</span>
###xml 190 195 <span type="species:ncbi:9606">human</span>
###xml 231 240 <span type="species:ncbi:5861">P. yoelii</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
(A) Groups of 2-3 FcgammaRI transgenic (Tg) or nontransgenic (NTg) littermates were injected i.p. with a total dose of 1.5 mg fully human anti-P. falciparum MSP119 IgG1 (JS1), an irrelevant human IgG1 (B10) recognizing MSP119 from P. yoelii or PBS. Similar results were obtained in two independent experiments. **Only groups of mice given JS1 in the FcgammaRI Tg were significantly different to all the other control groups with a p < 0.01. dagger, death of mice.
###end p 135
###begin p 136
###xml 458 471 450 463 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">P. falciparum</named-content>
###xml 476 478 468 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 831 834 815 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 447 452 <span type="species:ncbi:9606">human</span>
###xml 458 471 <span type="species:ncbi:5833">P. falciparum</span>
###xml 492 497 <span type="species:ncbi:9606">human</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 728 732 <span type="species:ncbi:10090">mice</span>
###xml 858 862 <span type="species:ncbi:10090">mice</span>
(B) Repeat experiment in FcgammaRI Tr animals using a lower total dose (0.75 mg) of JS1. Coadministration of the blocking mAb 10.1 specific for the IgG1 binding site on human FcgammaRI abrogates the protection mediated by the passively administered JS1 antibody. Each point represents the geometric mean parasitemia of mice in each group at the time after i.p. challenge with 5,000 parasitized erythrocytes. Only those animals receiving the fully human anti-P. falciparum MSP119 IgG1 Ab in a human FcgammaRI background survived an otherwise lethal infection; all the mice in the other groups with high parasitemias were killed on either day 7 or 8. Similar results were obtained in two independent experiments. **Only groups of mice given JS1 in the FcgammaRI Tg were significantly different to all the other control groups with a p < 0.01. dagger, death of mice.
###end p 136
###begin p 137
(C-E) x100 magnification of Giemsa-stained smears of blood taken from control animals (C) and FcgammaRI Tg animals treated with JS1 (D and E). Note the presence of phagocytosed merozoites within the cytoplasm of cells displaying mononuclear morphology (arrow).
###end p 137
###begin p 138
###xml 74 76 74 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19</sub>
###xml 118 123 <span type="species:ncbi:9606">Human</span>
###xml 171 176 <span type="species:ncbi:10090">Mouse</span>
The Location of Amino Acid Residues and the Modifications Made within MSP119 and Their Effect on the Binding by Fully Human IgG1 (JS1 and JS2) or Previously Characterized Mouse mAbs 12.8 and 12.10
###end p 138
###begin p 139
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. AAH and RJP share senior authorship. RSM, JS, TS, and ML performed all animal experiments, Biacore analysis, generation of Abs, and ELISAs. RMJ, JCC, and TSJ designed and constructed the phage libraries and contributed to discussion. JG conducted inhibition of processing assays. MvE, JHWL, and JvdW provided transgenic animals and important critique. TFdKW and BSC provided transgenic parasites, contributed IFA data, and read many drafts. AAH and RJP conceived and designed the overall study, provided laboratory facilities, and wrote the paper.
###end p 139
###begin p 140
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This study was funded by a Medical Research Council Career Establishment Award (G0300145) and a European Union Marie Curie Excellence Grant, Antibody Immunotherapy for Malaria (MEXT-CT-2003-509670) to RJP, and a ROPA (Realizing Our Potential Award) to AAH.
###end p 140
###begin p 141
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 141

